T. Rowe Price Investment Management
IMCR icon

T. Rowe Price Investment Management’s Immunocore IMCR Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,891,600
Closed -$57M – 776
2026
Q1 		$57M Sell
1,891,600
-4,069,627
-68% -$132M 0.04% 329
2025
Q4 		$207M Sell
5,961,227
-1,102,669
-16% -$38.9M 0.13% 165
2025
Q3 		$257M Sell
7,063,896
-3,763
-0.1% -$128K 0.16% 144
2025
Q2 		$222M Buy
7,067,659
+15,841
+0.2% +$492K 0.14% 168
2025
Q1 		$209M Buy
7,051,818
+351,610
+5% +$10.5M 0.14% 166
2024
Q4 		$198M Buy
6,700,208
+200,373
+3% +$6.33M 0.12% 180
2024
Q3 		$202M Buy
6,499,835
+3,507,562
+117% +$128M 0.12% 183
2024
Q2 		$101M Buy
2,992,273
+2,258,662
+308% +$115M 0.06% 279
2024
Q1 		$47.7M Buy
733,611
+359,050
+96% +$24.6M 0.03% 403
2023
Q4 		$25.6M Buy
+374,561
New +$19.5M 0.02% 467

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Investment Management's IMCR Position: Q2 2026 in Review

T. Rowe Price Investment Management sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 1,891,600 shares — an estimated $57M sold.

T. Rowe Price Investment Management first reported a position in IMCR in Q4 2023 and held it in 10 quarters. The position peaked at $257M in Q3 2025. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • T. Rowe Price Investment Management reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,891,600 Immunocore shares in Q2 2026, an estimated $57M.
  • T. Rowe Price Investment Management first reported a position in Immunocore in Q4 2023 and held it in 10 quarters.
  • T. Rowe Price Investment Management's Immunocore position peaked at $257M in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.